Meghatározza-e az oldaliság az irreszekábilis metasztatikus colorectalis carcinoma elso vonalbeli kezelését?

Translated title of the contribution: Does the sidedness determine the first line treatment of irresectable metastatic colorectal cancer?

Kullmann Tamás, Sipocz István, T. Pintér

Research output: Contribution to journalArticle

Abstract

Introduction and aim: Median life expectancy of non-resectable metastatic colorectal cancer may surpass three years. However, several points of the treatment strategy are subject of ongoing debate. Optimal sequence of targeted agents is not elucidated either. Based on retrospective analyses of six clinical studies and a metaanalysis, the superiority of anti-EGFR agents such as cetuximab and panitumumab over anti-VEGF bevacizumab has been proposed in the treatment of left sided tumours. Method: The results of the six major clinical trials were analysed. Insufficiencies of the meta-analysis are pointed: the lack of homogeneity among control groups, the omission of later lines of therapy, the inconsistency between progression free and overall survival benefit and the high proportion of excluded patients. Results: The trials confirm the worse prognosis of right sided versus left sided colorectal cancers. Conclusion: To date the data are not strong enough to support the preference of any of the available targeted agents at the first line setting in the treatment of left sided metastatic RAS and BRAF wild type colorectal cancers. Several trials suggest that anti-EGFR treatment has no additional benefit as compared to chemotherapy alone in the treatment of right-sided tumours.

Original languageHungarian
Pages (from-to)340-344
Number of pages5
JournalOrvosi Hetilap
Volume158
Issue number9
DOIs
Publication statusPublished - Mar 1 2017

Fingerprint

Colorectal Neoplasms
Therapeutics
Life Expectancy
Vascular Endothelial Growth Factor A
Disease-Free Survival
Meta-Analysis
Neoplasms
Clinical Trials
Drug Therapy
Control Groups

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Meghatározza-e az oldaliság az irreszekábilis metasztatikus colorectalis carcinoma elso vonalbeli kezelését? / Tamás, Kullmann; István, Sipocz; Pintér, T.

In: Orvosi Hetilap, Vol. 158, No. 9, 01.03.2017, p. 340-344.

Research output: Contribution to journalArticle

@article{8eeb49ca052b4650aae7b634e731ca7e,
title = "Meghat{\'a}rozza-e az oldalis{\'a}g az irreszek{\'a}bilis metasztatikus colorectalis carcinoma elso vonalbeli kezel{\'e}s{\'e}t?",
abstract = "Introduction and aim: Median life expectancy of non-resectable metastatic colorectal cancer may surpass three years. However, several points of the treatment strategy are subject of ongoing debate. Optimal sequence of targeted agents is not elucidated either. Based on retrospective analyses of six clinical studies and a metaanalysis, the superiority of anti-EGFR agents such as cetuximab and panitumumab over anti-VEGF bevacizumab has been proposed in the treatment of left sided tumours. Method: The results of the six major clinical trials were analysed. Insufficiencies of the meta-analysis are pointed: the lack of homogeneity among control groups, the omission of later lines of therapy, the inconsistency between progression free and overall survival benefit and the high proportion of excluded patients. Results: The trials confirm the worse prognosis of right sided versus left sided colorectal cancers. Conclusion: To date the data are not strong enough to support the preference of any of the available targeted agents at the first line setting in the treatment of left sided metastatic RAS and BRAF wild type colorectal cancers. Several trials suggest that anti-EGFR treatment has no additional benefit as compared to chemotherapy alone in the treatment of right-sided tumours.",
keywords = "Bevacizumab, Cetuximab, Chemotherapy, Metastatic colorectal cancer, Panitumumab",
author = "Kullmann Tam{\'a}s and Sipocz Istv{\'a}n and T. Pint{\'e}r",
year = "2017",
month = "3",
day = "1",
doi = "10.1556/650.2017.30682",
language = "Hungarian",
volume = "158",
pages = "340--344",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "9",

}

TY - JOUR

T1 - Meghatározza-e az oldaliság az irreszekábilis metasztatikus colorectalis carcinoma elso vonalbeli kezelését?

AU - Tamás, Kullmann

AU - István, Sipocz

AU - Pintér, T.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Introduction and aim: Median life expectancy of non-resectable metastatic colorectal cancer may surpass three years. However, several points of the treatment strategy are subject of ongoing debate. Optimal sequence of targeted agents is not elucidated either. Based on retrospective analyses of six clinical studies and a metaanalysis, the superiority of anti-EGFR agents such as cetuximab and panitumumab over anti-VEGF bevacizumab has been proposed in the treatment of left sided tumours. Method: The results of the six major clinical trials were analysed. Insufficiencies of the meta-analysis are pointed: the lack of homogeneity among control groups, the omission of later lines of therapy, the inconsistency between progression free and overall survival benefit and the high proportion of excluded patients. Results: The trials confirm the worse prognosis of right sided versus left sided colorectal cancers. Conclusion: To date the data are not strong enough to support the preference of any of the available targeted agents at the first line setting in the treatment of left sided metastatic RAS and BRAF wild type colorectal cancers. Several trials suggest that anti-EGFR treatment has no additional benefit as compared to chemotherapy alone in the treatment of right-sided tumours.

AB - Introduction and aim: Median life expectancy of non-resectable metastatic colorectal cancer may surpass three years. However, several points of the treatment strategy are subject of ongoing debate. Optimal sequence of targeted agents is not elucidated either. Based on retrospective analyses of six clinical studies and a metaanalysis, the superiority of anti-EGFR agents such as cetuximab and panitumumab over anti-VEGF bevacizumab has been proposed in the treatment of left sided tumours. Method: The results of the six major clinical trials were analysed. Insufficiencies of the meta-analysis are pointed: the lack of homogeneity among control groups, the omission of later lines of therapy, the inconsistency between progression free and overall survival benefit and the high proportion of excluded patients. Results: The trials confirm the worse prognosis of right sided versus left sided colorectal cancers. Conclusion: To date the data are not strong enough to support the preference of any of the available targeted agents at the first line setting in the treatment of left sided metastatic RAS and BRAF wild type colorectal cancers. Several trials suggest that anti-EGFR treatment has no additional benefit as compared to chemotherapy alone in the treatment of right-sided tumours.

KW - Bevacizumab

KW - Cetuximab

KW - Chemotherapy

KW - Metastatic colorectal cancer

KW - Panitumumab

UR - http://www.scopus.com/inward/record.url?scp=85018722035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018722035&partnerID=8YFLogxK

U2 - 10.1556/650.2017.30682

DO - 10.1556/650.2017.30682

M3 - Article

VL - 158

SP - 340

EP - 344

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 9

ER -